Gene: TMEM184A
Official Full Name: transmembrane protein 184Aprovided by HGNC
Gene Summary: Predicted to enable heparin binding activity and transmembrane transporter activity. Predicted to be involved in transmembrane transport. Predicted to act upstream of or within germ-line sex determination; regulation of protein localization; and regulation of secretion. Predicted to be located in cytoplasmic vesicle; perinuclear region of cytoplasm; and plasma membrane. Predicted to be active in early endosome membrane. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO36302 | TMEM184A Knockout cell line (HeLa) | Human | TMEM184A | 1:3~1:6 | Negative | Online Inquiry |
KO36303 | TMEM184A Knockout cell line (HCT 116) | Human | TMEM184A | 1:2~1:4 | Negative | Online Inquiry |
KO36304 | TMEM184A Knockout cell line (HEK293) | Human | TMEM184A | 1:3~1:6 | Negative | Online Inquiry |
KO36305 | TMEM184A Knockout cell line (A549) | Human | TMEM184A | 1:3~1:4 | Negative | Online Inquiry |
TMEM184A Gene Knockout Cell Lines are specially engineered cellular models designed to study the biological functions and therapeutic implications of the TMEM184A gene. These cell lines are created using CRISPR-Cas9 technology to induce precise mutations that completely eliminate TMEM184A expression. By serving as a valuable tool for functional genomics, researchers can explore the role of TMEM184A in various cellular pathways, immune responses, and disease states, particularly in cancer and neurodegenerative disorders.
The primary mechanism of these knockout cell lines hinges on the targeted disruption of the TMEM184A gene, which allows scientists to investigate how the absence of this protein affects cellular functions such as proliferation, differentiation, and apoptosis. This insight is crucial for understanding the gene's involvement in regulatory mechanisms and its potential as a therapeutic target.
In research and clinical settings, these knockout models are indispensable for elucidating the gene's role in disease progression and for validating novel treatments. By examining the phenotypic consequences of gene knockout, researchers can uncover vital information regarding TMEM184A as a potential biomarker or target for drug development.
Unlike alternative gene knockout models, our TMEM184A Gene Knockout Cell Lines offer optimal consistency, purity, and reproducibility, ensuring that experimental results are both robust and reliable. They provide researchers with a straightforward and efficient way to study TMEM184A, significantly reducing time and resource expenditures typically associated with earlier knockout methodologies.
Valuable to researchers and clinicians alike, these cell lines empower scientists with the capacity to advance their investigations into gene function and its implications in human health and disease. Our commitment at [Company Name] to cutting-edge biotechnological solutions makes us leaders in producing high-quality biological products. With our TMEM184A Gene Knockout Cell Lines, you can accelerate your research, increase the reproducibility of your findings, and contribute significantly to the broader scientific community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.